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Abstract
Background: Over the last decade there have been a number of guidelines published, aimed at improving the
quality of reporting in published studies and reviews. In systematic reviews this may be measured by their
compliance with the PRISMA statement. This review aims to evaluate the quality of reporting in published meta-
analyses of diagnostic tests, using the PRISMA statement and establish whether there has been a measurable
improvement over time.
Methods: Eight databases were searched for reviews published prior to 31
st December 2008. Studies were selected
if they evaluated a diagnostic test, measured performance, searched two or more databases, stated the search
terms and inclusion criteria, and used a statistical method to summarise a test’s performance. Data were extracted
on the review characteristics and items of the PRISMA statement. To measure the change in the quality of
reporting over time, PRISMA items for two periods of equal duration were compared.
Results: Compliance with the PRISMA statement was generally poor: none of the reviews completely adhered to
all 27 checklist items. Of the 236 meta-analyses included following selection: only 2(1%) reported the study
protocol; 59(25%) reported the searches used; 76(32%) reported the results of a risk of bias assessment; and 82
(35%) reported the abstract as a structured summary. Only 11 studies were published before 2000. Thus, the
impact of QUOROM on the quality of reporting was not evaluated. However, the periods 2001-2004 and 2005-2008
(covering 93% of studies) were compared using relative risks (RR). There was an increase in the proportion of
reviews reporting on five PRISMA items: eligibility criteria (RR 1.13, 95% CI 1.00 - 1.27); risk of bias across studies
(methods) (RR 1.81, 95% CI 1.34 - 2.44); study selection results (RR 1.48, 95% CI 1.05 - 2.09); results of individual
studies (RR 1.37, 95% CI 1.09 - 1.72); risk of bias across studies (results) (RR 1.65, 95% CI 1.20 - 2.25).
Conclusion: Although there has been an improvement in the quality of meta-analyses in diagnostic research,
there are still many deficiencies in the reporting which future reviewers need to address if readers are to trust the
validity of the reported findings.
Background
Systematic reviews have become increasingly important
in diagnostic research [1,2]. With the development of
new statistical methods used to aggregate primary stu-
dies [3,4], and increasing numbers of diagnostic reviews
appearing in the literature [1,2], the need for high qual-
ity meta-analyses of diagnostic tests has, perhaps, never
been greater.
Unfortunately, like all other types of systematic
reviews, they are prone to a number of shortcomings.
These may arise at a review level, due to inaccessibility
to all pertinent studies [5], failings in the selection pro-
cess [6], or heterogeneity [7,8], which often blights
reviews of diagnostic tests [2]. They may also arise at a
primary study level, due to flaws in the design, execu-
tion and reporting of the component studies [9,10].
To help identify and mitigate potential weaknesses,
quality assessment of the primary studies has become an
intrinsic element of the review process [11]. Following
the publication of the Standards for the Reporting of
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which set out to improve the reporting of primary
research on diagnostic tests, the assessment of quality
has been recently formalized. The Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) tool [12] is a
generic tool that covers the major domains affecting
diagnostic study validity, thus placing quality assessment
on a firmer ground and allowing inter-study comparison.
There have been parallel developments in meta-analy-
sis. As major undertakings of work, their results may be
influential to health care providers, researchers, and
decision makers. Thus, the need for a consistent frame-
work of reporting was recognised. This led to the com-
pilation of the Quality of Reporting of Meta-analyses
(QUOROM) statement [13], which was aimed at
improving the quality of published meta-analyses of ran-
domised controlled trials. Recently, the QUOROM state-
ment [13] has been superseded by the Preferred
Reporting Items for Systematic Reviews and Meta-Ana-
lyses (PRISMA) statement [14]. This was in response to
developments in systematic review methodology and to
widen the scope beyond randomised controlled trials.
Currently this is the standard for investigators when
reporting their findings and also provides a benchmark
by which meta-analyses may be appraised.
Meta-analyses of diagnostic tests will potentially have
an increasing role in healthcare as decision makers look
to the evidence before implementing new diagnostic
technologies. It is important that such analyses provide
reliable results and this, in part, is determined by the
quality of reporting [2,14,15].
As meta-analysis in diagnostic research has been devel-
oping for nearly two decades, it is an appropriate time to
assess the overall quality of reporting of meta-analyses of
diagnostic test studies. Furthermore it is of interest to
know whether there has been a measureable improvement
in the quality of reporting. Thus, the objective of this sys-
tematic review was to examine the quality of reporting of
published meta-analyses of diagnostic tests studies, by
their compliance with the PRISMA statement and to
assess whether there is evidence of an improvement in the
overall quality of reporting. This review was part of a
wider investigation into meta-analyses of diagnostic test
accuracy studies that has been published elsewhere [16].
Methods
Data sources and searches
The electronic databases, Medline, CINAHL, Cochrane
library (including the Cochrane Database of Systematic
Reviews, DARE, Health Technology Assessment Data-
base and NHS Economic Evaluation Database)
EMBASE, PsychInfo, Global health, HMIC, and AMED
were all searched for relevant reviews (example search
algorithms are listed in Additional file 1). The searches
were conducted initially in September 2008 and updated
in September 2009. The cut off for inclusion of the
meta-analyses was December 31
st 2008.
Selection criteria
For the purpose of this review, the term ‘meta-analysis’
is taken to mean a special type of systematic review, in
which standard systematic review methodology has been
followed and a quantitative summary of the results has
been derived.
All citations retrieved from the electronic searches
were subject to a six-step algorithm for inclusion in the
review. The title and abstracts of the citations were initi-
ally screened using step 1, before retrieving the full text.
Steps 2 to 6 were then applied to the full text of the
articles, where non-compliance with any of the steps
resulted in the article’s exclusion.
The steps in the inclusion criteria were as follows:
1 .I st h ec i t a t i o na no r i g i n a ls t u d yo fad i a g n o s t i c /
screening test?
2. Was one of the objectives to measure the test(s)
performance?
3. Were two or more of the major databases searched
to identify the relevant articles? Examples included
MEDLINE, EMBASE, Cochrane, and CINAHL.
4. Were the search terms explicitly stated?
5. Were the inclusion criteria explicitly stated?
6. Was at least one statistical method used to sum-
marize the overall test performance across the primary
studies?
The first criterion (step 1) requires clarification as it
encompasses a number of terms. The word original was
defined here as a primary or secondary (systematic
review) evaluation of the technology. Narrative reviews,
editorials and commentaries were excluded, although
primary studies were still included at this stage. A diag-
nostic/screening test was defined as a technology aimed
at identifying a target disorder, which was present at the
time of testing. Target disorders were considered to be
pathological processes and not related to a success or
failure of an intervention, such as successful placing of
stents. Furthermore, technologies, which predicted the
future occurrence of a target disorder, which was not
present at the time of testing, were not considered diag-
nostic technologies in this review.
The question of what constitutes a systematic review
is, to a degree, open to debate. But the view taken here
is that, an important part of the systematic review pro-
cess is that investigators should make every effort to
identify all the relevant studies. Since research has
demonstrated that to search a single database runs a
high risk of missing relevant studies [17,18], a minimum
requirement that investigators should have searched two
or more databases was imposed in the inclusion criteria.
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inclusion criteria to all the citations and reviews. The
second author (MQ) independently screened and
applied the inclusion criteria to a random sample of
10% of all the citations, and discrepancies were decided
by consensus agreement.
Data extraction and quality assessment
Data were abstracted on the following items: publica-
tion year; objective; diagnostic test; target disorder;
search terms (or whether an algorithm was given);
databases searched; inclusion criteria (and whether
they were made explicit); process of data extraction;
method used to assess quality including QUADAS
[12]; presence of heterogeneity; and responses to the
PRISMA statement [14].
The PRISMA statement was used to evaluate the over-
all quality of reporting of the meta-analyses and consists
of a twenty seven-point checklist. To indicate the degree
of compliance, each checklist item was assigned one of
three responses: ‘yes’ for total compliance; ‘partial’ for
partial compliance; and ‘no’ for non-compliance. As a
large number of checklist items may not be satisfactorily
answered with a binary response (yes/no), the inter-
mediate category (partial) was included to represent the
situation where a review had satisfied some, but not all
of the criteria for an individual item.
Extraction of data was performed by BHW and inde-
pendently on a random sample of 10%, by MQ. Discre-
pancies were decided by consensus agreement.
Data synthesis and analysis
For making comparisons over time, two cohorts of equal
duration were compared.
Ideally, these would have been periods either side of
the introduction of the QUOROM statement (published
in November 1999) so that the impact it had on the
quality of reporting could be evaluated. Unfortunately,
the sample size of studies prior to its introduction was
too small to address this question adequately. Hence,
both periods were chosen to be later than the publica-
tion of QUOROM to avoid it having a heterogeneous
effect on one of the cohorts (see Results).
When analysing responses to the PRISMA statement
[14], the relative risk or risk ratio was used as the sum-
mary statistic for sub-group comparisons [19,20]. If the
relative risk was undefined, then Fisher’se x a c tt e s tw a s
used [21]. Statistical significance was set at p < 0.05.
Where appropriate, the kappa statistic was used to
assess the level of agreement between the reviewers
[22,23], and interpretation was made using accepted cri-
teria [23,24]. For all statistical analyses, EXCEL and the
programming software R (version 2.10.1) were used.
Results
Over 4000 unduplicated citations were retrieved from
the electronic searches and after applying the selection
criteria 236 articles were included for appraisal (Figure
1). For a list of the included reviews see Additional file
2. As measured by the kappa score, agreement between
the reviewers on review selection was excellent, with a
kappa score of 0.86. Disagreements were over the stage
in which certain reviews were excluded, not the decision
whether to exclude. Thus, there was 100% agreement on
which reviews to include. For the PRISMA items, the
median kappa score between the two reviewers was 0.88
(range: 0.66 - 1).
Characteristics of the included reviews
The majority of the included reviews were reported in
specialist journals (78%), with 39 (17%) being published
in radiology journals. Thirty meta-analyses were
reported in general medical journals, such as the BMJ or
Annals of Internal Medicine and 15 were commissioned
health technology assessments (HTA).
Figure 2 illustrates the number of reviews per publica-
tion year in the included set. Nearly 93% (219 meta-ana-
lyses) were published after the year 2001.
A wide range of diagnostic tests featured in the
reviews, with imaging technologies (47%) being the most
common category of test evaluated. These included 45
reviews on ultrasound tests, 42 on computer tomogra-
phy and 34 on magnetic resonance imaging. Nearly a
fifth of reviews investigated diagnostic tests found in the
clinical examination and 35 (15%) evaluated biochemical
tests.
An equally diverse spectrum of target disorders was
covered by the reviews. Cancer (25%) and infection (20%)
were the two most frequent categories of target disorder
in the reviews; 20 reviews evaluated diagnostic tests used
to detect tuberculosis alone (the characteristics of the
individual reviews are detailed elsewhere [16]).
Quality of reporting and compliance with PRISMA (table 1)
Generally compliance with PRISMA was poor: none of
the 27 checklist criteria was complied with by all
reviews, nor did any one review fulfil all 27 items of
PRISMA.
All of the reviews did at least achieve partial compli-
ance in nearly a third (8/27) of the criteria.
However, some of these items relate to the definition
of a systematic review and coincide with the eligibility
criteria for this study. Thus a review’s partial compliance
with PRISMA items 6,7,8 and 14 follows directly from
its eligibility for inclusion in this study. Full details of
applying the PRISMA statement to each of the included
meta-analyses are given in Additional file 3.
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quately reported in over 95% of the reviews and these
included: the rationale for the review; the description of
the data sources; the measures used to summarize the
primary studies; the methods used to aggregate the
data; the results of the meta-analysis; a summary of the
main findings and the concluding remarks in the
discussion.
Unduplicated citations retrieved 
from searches 
Apply step 1 to title and 
abstract  
Retrieve full text articles 
Step 1 full text review 
Step 2 
Include 1048 
Outstanding 9 
Step 6 
Include  236 
4336 
Exclude 3288 
Narrative reviews, editorials, 
abstracts & foreign language 
studies. Eight were publications 
also published as HTA reports 
Unable to locate                  9 
Retrieved 1039 
Step 3 
Step 4 
Step 5 
Include 881 
Include 751 
Include 384 
Include 328 
Include 304 
Exclude 158 
Exclude 130 
Exclude 367 
Exclude 56 
Exclude 24 
Exclude 68 
Abstracts, editorials & narrative 
reviews, or not a diagnostic 
studies 
Did not ascertain acceptable 
diagnostic measures 
Did not list 3 or more search 
terms 
Did not search 2 or more 
electronic databases 
Did not explicitly state 
inclusion criteria 
Did not use acceptable 
summary statistical methods. 
Figure 1 Flowchart of studies showing results of applying the inclusion criteria. Also shown are the types of study or reasons for
exclusion.
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Figure 2 Number of included meta-analyses per year of publication.
Table 1 Summary of the results of applying the PRISMA statement to the individual meta-analyses
PRISMA statement results
Yes Partial No
Title 1 Title 221 (93%) 13 (5%) 2 (0%)
Abstract 2 Structured summary 82 (35%) 147 (62%) 7 (3%)
Introduction 3 Rationale 233 (98%) 3 (1%) 0 (0%)
Methods 4 Objectives 143 (60%) 90 (38%) 3 (1%)
5 Protocol and registration 2 (1%) 35 (15%) 199 (84%)
6 Eligibility criteria 209 (88%) 27 (11%) 0 (0%)
7 Information sources 235 (99%) 1 (0%) 0 (0%)
8 Search 59 (25%) 177 (75%) 0 (0%)
9 Study selection 134 (57%) 30 (13%) 72 (30%)
10 Data collection process 149 (63%) 16 (7%) 71 (30%)
11 Data items 127 (54%) 64 (27%) 45 (19%)
12 Risk of bias in individual studies 103 (43%) 79 (33%) 54 (23%)
13 Summary measures 235 (99%) 0 (0%) 1 (0%)
14 Synthesis of results 234 (99%) 2 (1%) 0 (0%)
15 Risk of bias across studies 152 (64%) 30 (13%) 54 (23%)
16 Additional analyses 101 (43%) 12 (5%) 123 (52%)
Results 17 Study selection 112 (47%) 91 (38%) 33 (14%)
18 Study characteristics 132 (56%) 94 (40%) 10 (4%)
19 Risk of bias within studies 76 (32%) 84 (36%) 76 (32%)
20 Results of individual studies 162 (68%) 36 (15%) 39 (16%)
21 Synthesis of results 235 (99%) 1 (0%) 0 (0%)
22 Risk of bias across studies 136 (57%) 35 (15%) 65 (27%)
23 Additional analyses 90 (38%) 24 (10%) 122 (51%)
Discussion 24 Summary of evidence 232 (98%) 4 (2%) 0 (0%)
25 Limitations 139 (59%) 38 (16%) 59 (25%)
26 Conclusions 232 (98%) 4 (2%) 0 (0%)
Funding 27 Funding 114 (48%) 0 (0%) 122 (51%)
Willis and Quigley BMC Medical Research Methodology 2011, 11:163
http://www.biomedcentral.com/1471-2288/11/163
Page 5 of 11In over 84% (199/236) of publications the existence of
a review protocol, or whether the review had been regis-
tered, was not reported. The test being investigated was
usually stated in the objective, but, in general, the
reporting in the included reviews fell short of stating
clear focused objectives. In six reviews the objective was
not clear at all (see Additional file 4)
Search algorithms used to locate the primary studies
were reported in only 23% (55/236) of the meta-analyses.
In a number of the included reviews, the reference lists
of the primary studies were searched, for further cita-
tions. Nevertheless, in over a third, the searches were
confined to only two electronic databases, principally
Medline and EMBASE, thereby diminishing the likeli-
hood of achieving completeness (see Additional file 4).
In all of the reviews, the eligibility criteria were expli-
citly stated in the methods; however, there was signifi-
cant variability in the clarity of terminology and in only
67 (28%) reviews could they be feasibly described as
being algorithmic. The process of selection was also
variable: in only 96 (41%) reviews was it clearly
d e s c r i b e dt h a ta tl e a s tt w oi nvestigators had indepen-
dently screened, selected and abstracted data from the
primary studies (see Additional file 4).
From the PRISMA analysis, screening and eligibility
results were displayed in the form of a flow chart in 113
(48%) reviews. However, on closer inspection, only 44
(19%) of these meta-analyses gave sufficient information
on the decisions behind including or excluding the pri-
mary studies. Either the reason was not given, or vague
terms, such as ‘not relevant’, were used without elabora-
tion (see Additional file 4).
The descriptions of data abstraction also varied widely.
In 103 (43%) reviews, the authors were unclear on either
the abstraction process or the data items abstracted
(Additional file 4). Many reviews listed no more than
abstracting data to complete 2 × 2 tables, when clearly
other information had been sought from the primary
studies. In eighteen reviews, data abstraction was not
reported at all.
For more than half of the reviews (123/236), addi-
tional analyses in the methods, such as meta-regression
or sub-group analyses, were not described. In a similar
proportion there was neither reporting of the results of
any additional analyses (52%) nor whether the review
had been funded (52%).
Comparison of meta-analyses published between 2001-
2004 and 2005-2008
To determine whether there had been an improvement
in the quality of reporting over time, cohorts of meta-
analyses published over periods of similar duration were
compared. The question of what impact the QUOROM
statement had on the quality of reporting was not
addressed, owing to the small sample size of the studies
published before QUOROM (11 included studies).
Therefore, the period 2001-2004 (63 reviews) was
compared with 2005-2008 (156 reviews) for full compli-
ance in each of the PRISMA criteria. Although not pre-
specified at the inception stage of the review, the peri-
ods 2001-2004 and 2005-2008 were chosen as they not
only capture the vast majority of reviews, both are later
than the publication of the QUOROM statement
(November 1999). The advantage of this latter point is
that the earlier cohort does not contain studies pub-
lished both pre and post publication of QUOROM and
so is less likely to be heterogeneous.
Over the two periods, there was a significant improve-
ment demonstrated in five of the criteria and these are
i l l u s t r a t e di nF i g u r e3 .I no n l yo n eo ft h ei t e m s
(abstract) was the reporting poorer in the later period
(Figure 3). In the previous decade there also seems to
have been an improvement in the number of reviews
reporting on the assessment of the quality of the pri-
mary studies. Over 50% of the reviews published in
2000 reported no formal quality assessment of the pri-
mary studies, compared with 20% in 2008. This has
coincided with a greater number of investigators using
the QUADAS tool for quality assessment, although
other methods of quality assessment continue to be
used (see Figure 4).
As already noted, some items of the PRISMA state-
ment feature in the eligibility criteria for this review.
The effect is to potentially increase compliance with
these items across both periods and bias the relative risk
towards 1. This explains the relative risks and narrow
confidence intervals observed in items 7 and 14 of Fig-
ure 3.
Comparison of HTA reports with other meta-analyses
In the included reviews there were 15 Health technology
assessment (HTA) reports. These are often commis-
sioned reports conducted by experienced reviewers with
a remit of providing ‘high quality research information
for decision makers’ [25] and are not constrained by the
word count restrictions imposed by many journals. As
might be expected, the reporting in these was of a
higher quality. In nine of the PRISMA criteria, there
was a significantly higher proportion of HTA reviews
adequately reporting on these, compared with the other
meta-analyses (see Figure 5). For the individual results
of applying PRISMA, refer to Additional file 3.
Sensitivity analysis
The HTA reports could potentially confound the differ-
ences in the quality observed between years 2001-2004
and 2005-2008, particularly if a disproportionate number
were in the second cohort (2005-2008). There were 10
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published between 2001-2004 (ratio of 2.5:1). Thus, com-
pared with the overall distribution of meta-analyses, (156
reviews published between 2005-2008 and 63 published
between 2001-2004, a ratio of 2.47:1) there were a similar
proportion of HTA reports in the later cohort.
To test whether this affected the results, a sensitivity
analysis was conducted, where the HTA reports were
#  2001  -2004  2005  -2008  RR  (95%   CI) 
1  58  /63  146  /156  1.02  (0.93  -1.11) 
2  30  /63  48  /156  0.65  (0.46  -0.92) 
3  62  /63  154  /156  1.00  (0.97  -1.04) 
4  37  /63  101  /156  1.10  (0.87  -1.40) 
5  1  /63  1  /156  0.40  (0.04  -3.82) 
6  52  /63  145  /156  1.13  (1.00  -1.27) 
7  63  /63  155  /156  0.99  (0.98  -1.01) 
8  12  /63  45  /156  1.51  (0.86  -2.67) 
9  38  /63  91  /156  0.97  (0.76  -1.23) 
10  37  /63  107  /156  1.17  (0.93  -1.47) 
11  29  /63  87  /156  1.21  (0.90  -1.64) 
12  28  /63  70  /156  1.01  (0.73  -1.40) 
13  62  /63  156  /156  1.02  (0.98  -1.05) 
14  61  /63  156  /156  1.03  (0.99  -1.08) 
15  27  /63  121  /156  1.81  (1.34  -2.44) 
16  22  /63  71  /156  1.30  (0.89  -1.90) 
17  24  /63  88  /156  1.48  (1.05  -2.09) 
18  34  /63  91  /156  1.08  (0.83  -1.41) 
19  21  /63  50  /156  0.96  (0.63  -1.46) 
20  36  /63  122  /156  1.37  (1.09  -1.72) 
21  62  /63  156  /156  1.02  (0.98  -1.05) 
22  26  /63  106  /156  1.65  (1.20  -2.25) 
23  18  /63  64  /156  1.44  (0.93  -2.22) 
24  61  /63  154  /156  1.02  (0.97  -1.07) 
25  31  /63  98  /156  1.28  (0.97  -1.69) 
26  60  /63  155  /156  1.04  (0.98  -1.11) 
27  34  /63  76  /156  0.90  (0.80  -1.19) 
 
Figure 3 Comparison of periods 2001-04 and 2005-08 by compliance with the PRISMA statement. The numbered items (#) correspond to
the PRISMA item numbers (see table 1). RR (95% CI) denotes the relative risk with the associated 95% confidence interval.
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
2000 2001 2002 2003 2004 2005 2006 2007 2008 
P
e
r
c
e
n
t
a
g
e
 
o
f
 
y
e
a
r
l
y
 
s
t
u
d
i
e
s
 
p
u
b
l
i
s
h
e
d
 
No quality assessment 
Other quality assessment 
QUADAS 
Figure 4 Changing pattern of quality assessment in meta-analyses of diagnostic tests. Comparison of the percentage of reviews
published per year using the QUADAS tool, other forms of quality assessment and no quality assessment. Earlier years not included due small
sample sizes (around 2 studies per year).
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Despite the exclusion of the HTA reports, the results
remained robust and the only significant PRISMA items
were those in the earlier analysis, that is, items 2, 6, 15,
17, 20 and 22 (Figure 6).
Discussion
Summary of evidence
The number of meta-analyses in diagnostic research is
increasing annually (Figure 2). From this review it seems
that, not only are investigators assessing the quality of
primary studies more often (Figure 4), but the quality of
reporting of the meta-analyses is also improving. A large
part of this is likely to result from the publishing of a
number of guidelines over the last decade. The intro-
duction of STARD [10], for primary studies on diagnos-
tic tests, was mirrored by QUOROM [13] and then later
PRISMA [14], for systematic reviews and meta-analyses.
These have undoubtedly helped standardise the quality
of reporting.
The need for high quality studies in health care, which
include meta-analyses of diagnostic tests, has probably
never been greater as the emphasis on evidence-based
decision-making increases. A corollary of this is a drive
for more complete and transparent reporting of how a
review has been designed and conducted, so that stake-
holders may make informed decisions on the validity of
the findings [20].
Although the quality of reporting of randomised con-
trolled trials has recently been reported by other authors
[20], we are not aware of such an assessment being made
on the quality of reporting of published systematic
reviews of diagnostic test studies. There was no restric-
tion on the type of journal, test, or target disorders being
sought. With a view of capturing those reviews, which
were unequivocally meta-analyses that had followed sys-
tematic review principles, the inclusion criteria were per-
haps tighter than reported in some other reviews [26].
Yet, despite the tighter inclusion criteria, this review
found their reporting was, in general, far from adequate
and having a number of shortcomings. Using the
PRISMA statement [14] it was shown that, although
there has been some improvement in certain aspects of
reporting over the last decade, for nine PRISMA items
#  HTA  Other  RR  (95%   CI) 
1  13  /15  208  /221  0.92  (0.75  -1.13) 
2  4  /15  78  /221  0.76  (0.32  -1.78) 
3  15  /15  218  /221  1.01  (1.00  -1.03) 
4  14  /15  129  /221  1.60  (1.34  -1.91) 
5  2  /15  0  /221       
6  14  /15  195  /221  1.06  (0.92  -1.22) 
7  15  /15  220  /221  1.00  (1.00  -1.01) 
8  15  /15  44  /221  5.02  (3.86  -6.54) 
9  13  /15  121  /221  1.58  (1.26  -2.00) 
10  14  /15  135  /221  1.53  (1.29  -1.81) 
11  13  /15  114  /221  1.68  (1.33  -2.13) 
12  8  /15  95  /221  1.24  (0.75  -2.04) 
13  15  /15  220  /221  1.00  (1.00  -1.01) 
14  15  /15  219  /221  1.01  (1.00  -1.02) 
15  10  /15  142  /221  1.04  (0.72  -1.50) 
16  7  /15  94  /221  1.10  (0.63  -1.93) 
17  10  /15  102  /221  1.44  (0.98  -2.12) 
18  12  /15  120  /221  1.47  (1.11  -1.95) 
19  6  /15  70  /221  1.26  (0.66  -2.42) 
20  14  /15  147  /221  1.40  (1.19  -1.65) 
21  15  /15  220  /221  1.00  (1.00  -1.01) 
22  10  /15  126  /221  1.17  (0.80  -1.70) 
23  6  /15  84  /221  1.05  (0.55  -2.00) 
24  15  /15  217  /221  1.02  (1.00  -1.04) 
25  10  /15  129  /221  1.14  (0.79  -1.66) 
26  15  /15  217  /221  1.02  (1.00  -1.04) 
27  14  /15  100  /221  2.06  (1.69  -2.52) 
Figure 5 Comparison of HTA reviews with other reviews using PRISMA. In nine PRISMA items the HTA reviews were significantly better
reported than in other types of reviews. The numbered items (#) correspond to the PRISMA item numbers (see table 1). In item #5, the relative
risk was undefined, but, Fisher’s exact test demonstrated a significant difference, (p = 0.0038), in favour of the HTA reports. RR (95% CI) denotes
the relative risk with the associated 95% confidence interval.
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Page 8 of 11less than half the meta-analyses were fully compliant.
Some of these may reflect inadequacies in the reporting
process, rather than flaws in the design or conduct of
the review. Nonetheless, these latter flaws cannot be dis-
counted [27-30]. For example, in 70% of the meta-ana-
lyses heterogeneity was reported as being present, yet it
was investigated in less than half: it is unlikely that this
difference is explained entirely by deficiencies in
reporting.
Despite these deficiencies it should be borne in mind
that, in addition to the spate of guidelines aimed at improv-
ing the quality of reporting [2,10,13], there have been a
number of developments in the statistical methodology
used in meta-analyses of diagnostic test accuracy studies
[3,4,31-33]. Increased dissemination of these methods
should lead to increased precision of the summary esti-
mates on a test’s performance, which in some instances,
should enhance the validity of the reported findings.
Limitations
There are limitations to this review. Like other recent
reviews on the quality of reporting [20], the review pro-
cess used here, predominately consisted of study selec-
tion and data extraction by a single reviewer. A second
reviewer performed independent verification of the
study selection and data extraction process on a 10%
random sample. Although inter-observer agreement
demonstrated ‘good to excellent agreement’ for selection
and data extraction, this method is still more likely to
yield errors than the preferred method of complete,
independent replication of both steps by the two
reviewers.
The definition of a systematic review is open to inter-
pretation. Chalmers and Altman described a systematic
review as a review, which had been prepared using a
‘systematic approach to minimising biases and random
errors’, with the different components of the process
#  2001  -2004  2005  -2008  RR  (95%   CI) 
1  54  /59  138  /146  1.03  (0.95  -1.13) 
2  29  /59  45  /146  0.63  (0.44  -0.89) 
3  58  /59  144  /146  1.00  (0.97  -1.04) 
4  33  /59  92  /146  1.13  (0.87  -1.46) 
5  0  /59  0  /146       
6  48  /59  136  /146  1.14  (1.01  -1.30) 
7  59  /59  145  /146  0.99  (0.98  -1.01) 
8  8  /59  35  /146  1.77  (0.87  -3.58) 
9  35  /59  82  /146  0.95  (0.73  -1.22) 
10  33  /59  98  /146  1.20  (0.93  -1.55) 
11  26  /59  78  /146  1.21  (0.88  -1.68) 
12  26  /59  64  /146  0.99  (0.71  -1.40) 
13  58  /59  146  /146  1.02  (0.98  -1.05) 
14  57  /59  146  /146  1.04  (0.99  -1.09) 
15  24  /59  114  /146  1.92  (1.39  -2.64) 
16  21  /59  66  /146  1.27  (0.86  -1.87) 
17  22  /59  81  /146  1.49  (1.04  -2.14) 
18  31  /59  83  /146  1.08  (0.82  -1.43) 
19  20  /59  45  /146  0.91  (0.59  -1.40) 
20  33  /59  112  /146  1.37  (1.08  -1.75) 
21  58  /59  146  /146  1.02  (0.98  -1.05) 
22  23  /59  99  /146  1.74  (1.24  -2.44) 
23  17  /59  60  /146  1.43  (0.91  -2.23) 
24  57  /59  144  /146  1.02  (0.97  -1.07) 
25  28  /59  91  /146  1.31  (0.98  -1.77) 
26  56  /59  145  /146  1.05  (0.98  -1.11) 
27  30  /59  67  /146  0.90  (0.66  -1.23) 

Figure 6 Sensitivity analysis. The HTA reports have been removed from the sample to check robustness of results. The numbered items (#)
correspond to the PRISMA item numbers (see table 1). In item #5, the relative risk was undefined, but, Fisher’s exact test demonstrated no
significant difference, (p = 1.00), between the two periods. Overall there was no change in the significance of results in any of the 27 PRISMA
items. RR (95% CI) denotes the relative risk with the associated 95% confidence interval.
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Page 9 of 11being documented in the ‘methods section’ [34]. The
Cochrane Handbook for Systematic Reviews on Inter-
ventions states that systematic reviews possess a number
of ‘key characteristics’ [35]. The eligibility criteria used
here were in line with these key characteristics and also
coincide with those items of PRISMA that help define a
systematic review. It follows that a review’si n c l u s i o n
guarantees it being at least partially compliant with four
items of PRISMA. Thus, the PRISMA statement cap-
tures more than the quality of reporting in systematic
reviews, it captures the essence of what defines a sys-
tematic review.
Clearly, if some of the eligibility criteria are relaxed
this would not only lead to additional studies being
included it would increase the likelihood of poorer com-
pliance with PRISMA. However, it then raises the ques-
tion of whether these additional studies are truly
systematic reviews if they do not possess some of the
‘key characteristics’ described by, perhaps, the leading
authority on systematic reviews [35]. As a result, the cri-
teria used here ensure that there was no ambiguity on
the type of reviews included. It also serves to reinforce
the conclusion that the quality of reporting in diagnostic
systematic reviews is far from adequate if deficiencies in
reporting are still being observed in a ‘more selective’
and therefore ‘higher quality’ group of studies.
This review is an analysis of the quality of reporting of
meta-analyses of diagnostic test studies published over
the previous decade. The issue of actual quality of the
reviews, as opposed to the quality of reporting, is more
difficult to assess, since the PRISMA statement is not a
direct measure of quality. Furthermore it is generic
checklist aimed at improving the reporting of all types
of systematic reviews and does not contain some of the
more specific nuances of diagnostic test reviews.
However, it does contain items on the reporting of the
process that lie behind the synthesis of a systematic
review, and the robustness of this process certainly contri-
butes to the overall quality. There may still be inaccuracies
between the reporting and how the review was actually
conducted, as has been shown with some primary studies
[27-30], nevertheless, it seems unreasonable not to con-
sider this as providing some measure of the overall quality
of the meta-analyses included in this review.
The included reviews represent a diverse group of
meta-analyses evaluating a range of diagnostic tests over
different settings and target disorders. It is unlikely that
quality of reporting will be completely independent of
variation in these and so the effect heterogeneity has on
the results needs to be considered.
Conclusion
In summary, this review demonstrates that the quality of
reporting of meta-analyses has measurably improved
over the previous decade. Unfortunately, there are still
many deficiencies, identified in the reporting of meta-
analyses of diagnostic test studies, which have been
highlighted. These need to be addressed by future inves-
tigators, if informed judgements on the validity and
reproducibility of the findings of their reviews are to be
made.
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